{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T21:14:44Z","timestamp":1648847684075},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.transci.2011.01.013","type":"journal-article","created":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T10:08:03Z","timestamp":1298455683000},"page":"179-182","source":"Crossref","is-referenced-by-count":0,"title":["Improving therapy for patients with aggressive lymphoma"],"prefix":"10.1016","volume":"44","author":[{"given":"James O.","family":"Armitage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7901","key":"10.1016\/j.transci.2011.01.013_b0005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(75)91142-3","article-title":"Advanced diffuse histiocytic lymphoma, a potentially curable disease","volume":"1","author":"DeVita","year":"1975","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.transci.2011.01.013_b0010","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1097-0142(197203)29:3<630::AID-CNCR2820290316>3.0.CO;2-Q","article-title":"Combination sequential chemotherapy in advanced reticulum cell sarcoma","volume":"29","author":"Levitt","year":"1972","journal-title":"Cancer"},{"key":"10.1016\/j.transci.2011.01.013_b0015","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma","volume":"89","year":"1997","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.transci.2011.01.013_b0020","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.transci.2011.01.013_b0025","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Armitage","year":"2008","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.transci.2011.01.013_b0030","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","article-title":"High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin\u2019s lymphoma","volume":"316","author":"Philip","year":"1987","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.transci.2011.01.013_b0035","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience","volume":"14","author":"Rodriguez","year":"2003","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.transci.2011.01.013_b0040","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.transci.2011.01.013_b0045","first-page":"6a","article-title":"Phase III trial of rituximab-CHOP(R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL)","volume":"102","author":"Habermann","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.transci.2011.01.013_b0050","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.transci.2011.01.013_b0055","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.transci.2011.01.013_b0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.transci.2011.01.013_b0065","first-page":"169","article-title":"R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse larage B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA Study","volume":"114","author":"Delarue","year":"2009","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.transci.2011.01.013_b0070","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers","volume":"26","author":"Wilson","year":"2008","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.transci.2011.01.013_b0075","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.transci.2011.01.013_b0080","doi-asserted-by":"crossref","first-page":"109a","DOI":"10.1182\/blood.V110.11.348.348","article-title":"Gene expression signatures predict overall survival in diffuse large B-cell lymphoma treated with rituximab and Chop-Like chemotherapy","volume":"110","author":"Lenz","year":"2007","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.transci.2011.01.013_b0085","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2007.15.9277","article-title":"Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma","volume":"26","author":"Fu","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2011.01.013_b0090","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"5","key":"10.1016\/j.transci.2011.01.013_b0095","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","article-title":"Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma","volume":"115","author":"Iqbal","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.transci.2011.01.013_b0100","first-page":"491","article-title":"Diagnosis and management of mycosis fungoides","volume":"24","author":"Galper","year":"2010","journal-title":"Oncology (Williston Park)"},{"issue":"13","key":"10.1016\/j.transci.2011.01.013_b0105","first-page":"1158","article-title":"Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders","volume":"23","author":"Kadin","year":"2009","journal-title":"Oncology (Williston Park)"},{"issue":"12","key":"10.1016\/j.transci.2011.01.013_b0110","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.transci.2011.01.013_b0115","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.transci.2011.01.013_b0120","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1470-2045(09)70265-7","article-title":"Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009","volume":"10","author":"Kwong","year":"2009","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.transci.2011.01.013_b0125","first-page":"94","article-title":"Biology and management of rare primary extranodal T-cell lymphomas","volume":"24","author":"Roschewski","year":"2010","journal-title":"Oncology (Williston Park)"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050211000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050211000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T21:13:08Z","timestamp":1592341988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050211000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S1473050211000292"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2011.01.013","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}